Clinical Significance of Intracytoplasmic nm23-H1 Expression in Diffuse Large B-Cell Lymphoma

DOI PDF PubMed 被引用文献4件 オープンアクセス
  • Nozomi Niitsu
    1Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa; The Adult Lymphoma Treatment Study Group (ALTSG).
  • Hirokazu Nakamine
    2Department of Clinical and Laboratory Medicine, Wakayama Medical University, Wakayama;
  • Masataka Okamoto
    3Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; and
  • Hiroko Akamatsu
    2Department of Clinical and Laboratory Medicine, Wakayama Medical University, Wakayama;
  • Masaaki Higashihara
    1Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa; The Adult Lymphoma Treatment Study Group (ALTSG).
  • Yoshio Honma
    4Saitama Cancer Center Research Institute, Saitama, Japan
  • Junko Okabe-Kado
    4Saitama Cancer Center Research Institute, Saitama, Japan
  • Masami Hirano
    3Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; and

書誌事項

公開日
2004-04-01
資源種別
journal article
DOI
  • 10.1158/1078-0432.ccr-03-0085
公開者
American Association for Cancer Research (AACR)

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p>Purpose: Recently, we established an ELISA technique for measuring nm23-H1 protein in serum and found that the serum nm23-H1 level is a potential prognostic factor for patients with non-Hodgkin’s lymphoma.</jats:p> <jats:p>Experimental Design: We used immunohistochemistry to examine the expression of nm23-H1 by the lymphoma cells in patients with diffuse large B-cell lymphoma (DLBCL).</jats:p> <jats:p>Results: By analyzing a consecutive series of 172 untreated DLBCL patients, we found that 100 (58.1%) were strongly positive. The cytoplasmic nm23 expression in lymphoma cells correlated significantly with the serum nm23-H1 level. There was a significant correlation between patients with cytoplasmic nm23-positive lymphoma and those with performance status 2–4, stage III/IV, bulky mass, B symptoms, elevated serum level of soluble interleukin 2 receptor, and elevated serum level of C-reactive protein. Overall and progression-free survival rates were significantly lower in patients with nm23-H1-positive lymphomas than in those with nm23-H1-negative lymphomas. Similar difference was seen between patients with high and low serum levels of nm23-H1. Thus, the correlation between presence or absence of cytoplasmic nm23-H1 expression and serum nm23-H1 levels suggests that serum nm23-H1 is produced directly by lymphoma cells.</jats:p> <jats:p>Conclusion: We suggest that nm23-H1 expression is a prognostic factor for DLBCL, and that it is as important as serum nm23-H1, both of which are useful for planning a treatment strategy.</jats:p>

収録刊行物

  • Clinical Cancer Research

    Clinical Cancer Research 10 (7), 2482-2490, 2004-04-01

    American Association for Cancer Research (AACR)

被引用文献 (4)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ